NICE recommends sotorasib for targeted treatment of advanced non-small cell lung cancer

The National Institute for Health and Care Excellence (NICE; London, UK) has recommended the pioneering drug sotorasib for the targeted treatment of KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC). In the UK, lung cancer is the third most common cancer with 48,000 newly diagnosed cases per year, with 85% of the cases being NSCLC. The KRAS G12C gene is the most frequently mutated gene seen in NSCLC; the mutation is seen in 12% of UK cases. Currently, the standard treatment for NSCLC is platinum-based immunotherapy or chemotherapy, with sotorasib being used after chemotherapy. Sotorasib, also known...